Wall Street analysts expect Insulet Co. (NASDAQ:PODD) to report sales of $162.28 million for the current quarter, Zacks reports. Nine analysts have provided estimates for Insulet’s earnings, with the lowest sales estimate coming in at $161.25 million and the highest estimate coming in at $163.49 million. Insulet reported sales of $130.52 million in the same quarter last year, which indicates a positive year over year growth rate of 24.3%. The company is expected to report its next quarterly earnings report on Wednesday, February 20th.

On average, analysts expect that Insulet will report full-year sales of $561.26 million for the current year, with estimates ranging from $560.17 million to $562.40 million. For the next financial year, analysts expect that the business will post sales of $690.59 million, with estimates ranging from $665.93 million to $729.68 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Insulet.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 1st. The medical instruments supplier reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.01. Insulet had a negative net margin of 2.54% and a negative return on equity of 7.63%. The company had revenue of $151.10 million for the quarter, compared to the consensus estimate of $148.82 million. During the same period in the previous year, the firm earned ($0.04) earnings per share. Insulet’s quarterly revenue was up 24.1% compared to the same quarter last year.

PODD has been the topic of a number of analyst reports. Leerink Swann reaffirmed an “outperform” rating and set a $130.00 target price on shares of Insulet in a research note on Tuesday, September 11th. Zacks Investment Research raised shares of Insulet from a “hold” rating to a “buy” rating and set a $119.00 price target on the stock in a research note on Monday, October 1st. UBS Group began coverage on shares of Insulet in a research note on Tuesday, November 27th. They issued a “buy” rating and a $105.00 price target on the stock. BidaskClub raised shares of Insulet from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 11th. Finally, Oppenheimer set a $100.00 price target on shares of Insulet and gave the company a “hold” rating in a research note on Friday, November 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $101.44.

In related news, EVP Aiman Abdel-Malek sold 602 shares of the company’s stock in a transaction that occurred on Friday, September 14th. The shares were sold at an average price of $107.99, for a total transaction of $65,009.98. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Shacey Petrovic sold 1,134 shares of the company’s stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $86.91, for a total transaction of $98,555.94. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 9,053 shares of company stock worth $756,844. 3.60% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in PODD. Principal Financial Group Inc. increased its stake in Insulet by 5.8% during the 1st quarter. Principal Financial Group Inc. now owns 37,618 shares of the medical instruments supplier’s stock worth $3,261,000 after buying an additional 2,076 shares during the period. Allianz Asset Management GmbH grew its holdings in Insulet by 24.4% during the 1st quarter. Allianz Asset Management GmbH now owns 20,749 shares of the medical instruments supplier’s stock worth $1,798,000 after acquiring an additional 4,074 shares in the last quarter. Bank of Montreal Can grew its holdings in Insulet by 312.1% during the 2nd quarter. Bank of Montreal Can now owns 8,313 shares of the medical instruments supplier’s stock worth $713,000 after acquiring an additional 6,296 shares in the last quarter. Amalgamated Bank grew its holdings in Insulet by 75.8% during the 2nd quarter. Amalgamated Bank now owns 13,645 shares of the medical instruments supplier’s stock worth $1,169,000 after acquiring an additional 5,883 shares in the last quarter. Finally, Aperio Group LLC grew its holdings in Insulet by 15.3% during the 2nd quarter. Aperio Group LLC now owns 4,976 shares of the medical instruments supplier’s stock worth $426,000 after acquiring an additional 660 shares in the last quarter.

PODD stock traded down $3.82 during trading on Wednesday, reaching $82.64. 1,106,727 shares of the stock were exchanged, compared to its average volume of 541,596. The company has a debt-to-equity ratio of 2.95, a current ratio of 4.58 and a quick ratio of 3.99. Insulet has a 1 year low of $67.43 and a 1 year high of $108.90. The company has a market capitalization of $4.96 billion, a PE ratio of -179.65 and a beta of 1.70.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

See Also: Cost of Capital

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.